FINWIRES · TerminalLIVE
FINWIRES

調査速報:CFRAはエスティローダー・カンパニーズ社の株式について「ホールド」の投資判断を維持します。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。予想を上回る第3四半期決算を受け、当社は12ヶ月目標株価を10ドル引き下げ、87ドルとします。これは、2027年度EPS予想の29倍(2026年度EPS予想の45倍からロールオーバー)に基づくもので、現在の株価の過去3年間の平均予想PER39倍を下回っています。2026年度EPS予想は2.16ドルから2.22ドルに、2027年度EPS予想は2.73ドルから2.99ドルにそれぞれ引き上げます。ELは関税コストにもかかわらず、売上総利益率が140ベーシスポイント改善し、営業利益率も360ベーシスポイント向上しました。経営陣は2027年度営業利益率についても前向きな見通しを示し、中間値で190ベーシスポイントの改善を示唆しました。これらの業績は市場予想を上回りましたが、主な要因はコスト削減、特に販売拠点の人員削減であると指摘します。現在の株価水準では、ELの中国市場の回復と既存ブランドの安定化がない限り、株価の上昇余地は限られています。しかし、フレグランス部門の第3四半期の堅調なオーガニック成長(+10%)と、2026年度のオーガニック成長率見通しの上方修正(+3%)によって、この上昇余地は相殺されます。現在の株価水準では、リスクとリターンのバランスが取れていると考えています。

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.

$LII